Indian pharma firm Wockhardt Limited has received permission from India’s Central Drugs Standard Control Organization to export up to 100 million doses of Russian Sputnik V COVID-19 vaccines. This includes up to 80 million doses of Sputnik Light and up to 20 million doses of Sputnik V Component I.
Wockhardt To Export 100 Million Sputnik Vaccines
News Comes Following Respectable Q3 Results For Indian Pharma Firm
Indian pharmaceutical firm Wockhardt is set to export up to 100 million doses of the Russian COVID-19 vaccine Sputnik V, through a technology transfer agreement with the Gamaleya National Research Institute of Epidemiology and Microbiology.
More from Earnings
• By
With sales and profits shooting up in 2024, Alvotech has revealed plans to rapidly accelerate development to add between four and six programs to its pipeline of biosimilars every year, while at the same time unveiling details of several new brands that it will be seeking to challenge. The firm has also set out longer-term financial targets that anticipate more than trebling its revenues in the next three years.
• By
The Chinese player reported its second profitable year in a row, with growth in sales reported across its marketed portfolio and further milestones in the near future.
• By
After announcing updates in its ongoing legal battle and a leadership shakeup earlier this fiscal year, Hyloris closed 2024 with a slight rise in revenue and a shrinking of its reported net loss.
• By
Months on from penning a landmark commercial and manufacturing agreement for GLP-1 assets with Metsera, Amneal says it is happy with how the partnership is shaping up.
More from Business
• By
With sales and profits shooting up in 2024, Alvotech has revealed plans to rapidly accelerate development to add between four and six programs to its pipeline of biosimilars every year, while at the same time unveiling details of several new brands that it will be seeking to challenge. The firm has also set out longer-term financial targets that anticipate more than trebling its revenues in the next three years.
• By
The Chinese player reported its second profitable year in a row, with growth in sales reported across its marketed portfolio and further milestones in the near future.
• By
India’s Dr Reddy’s and China’s Bio-Thera have struck a deal covering ustekinumab and golimumab biosimilars in multiple markets in south-east Asia.